You Only Live Twice

Agent 007 and the secret Japanese company Daiichi Sankyo must find and stop the true culprit of a series of attacks on visual and auditory regions of the brain in fibromyalgia patients.

live twice

Guess what I did today!

After only 5 hours sleep (I was up ‘til 3am with friends drinking vodka), I went to an appointment, stopped at the nursery to pick up some plants and soil, did some gardening, played with Kimba, finished the laundry and made some important phone-calls. Pretty cool, huh?

The appointment I went to was for another drug trial check-up. I bounced in, a little hung-over but full of beans. I’m feeling like the old me – could this be a second chance at my life?

The doctor and nurse practitioner looked on kinda stunned. (Remember, none of us know exactly what drug I’m taking.) I’m kinda stunned…on Sunday, I realised that I was happy – really happy – and I don’t know when I last felt happiness. I guess antidepressants just keep you on an even keel and you don’t realise that you’re not happy; you just know that you no longer feel so bad. I find myself singing to the radio where, before, I couldn’t handle the radio even being on.

Now, I may be the only person in the world feeling this kind of effect but I hope not. I would love all of you to start feeling this well. BUT, right now (3 weeks into the trial), I’m calling MIRACLE!

NOTE: Emeritus Research is still recruiting for the study, if anybody is interested. Click for  the Consent Form and information. Contact Daiichi using this email address – SM_DS5565_FM_Info@incresearch.com.

As well as the 1000 person study in the US and Canada, Daiichi is also recruiting in:

  • Campse and Coffs Harbour, NSW, Australia;
  • Maroochydore, Sherwood and Southport, Queensland, Australia;
  • Hobart, Tasmania, Australia;
  • Malvern East, Victoria, Australia;
  • Tallin and Tartu, Estonia;
  • Baldone, Jekabpils, Liepaja, Ogre and Riga, Latvia;
  • Auckland, Hamilton, Nelson, Tauranga and Wellington, New Zealand;
  • Banska Bystrica, Bratislava and Dubnica Nad Vahom, Slovakia; and,
  • Reading, Berkshire; Chesterfield, Derbyshire; Wellingborough, Northamptonshire: Atherstone, Warwickshire; and
  • Belfast, United Kingdom.

Posts in this series:

strip

Thunderball

007 heads to Malvern East to recover Good Health and Energy stolen by SPECTRE agent nicknamed Fibromyalgia in an international extortion scheme.

I have now been on the Daiichi Sankyo sanctioned medication for 7 days. It would be absolutely fantastic if my medication was the placebo because I’m feeling pretty damn good; and that would mean that my Fibromyalgia was gone.20151002_132317

090915 Kimba pot 1Today I woke up, took Kimba (my puppy) out for some play, did a load of washing, hung it out in the sun; and folded some dry laundry. A pretty good morning! So, I doubt that I’m on the placebo.

It hasn’t all been smooth sailing, though. A couple of nights ago, I had to put some ointment in a place that we don’t talk about in good company. It’s a reoccurrence of an ‘accident’ that happened quite a while ago. The wonderful ointment for this lovely and embarrassing condition has the possible (and very probable for us) side effects of headaches and dizziness. Ta Da! Two minutes after application, stabbing pain in the left side of my head – not happy, Jan! The minimal amount of Panadol that I am permitted (in the research study) couldn’t touch the pain. I knew that if I could just get rid of the headache (I was sure the headache was from the ointment and not the new drugs), I’d be okay. The headache (and extreme light sensitivity – you know how it is) lasted 3 days.

Today, I woke up…energised! Bring on the good feelings!

 

NOTE: Emeritus Research is still recruiting for the study, if anybody is interested. Click for  the Consent Form and information. Contact Daiichi using this email address – SM_DS5565_FM_Info@incresearch.com.

As well as the 1000 person study in the US and Canada, Daiichi is also recruiting in:

  • Campse and Coffs Harbour, NSW, Australia;
  • Maroochydore, Sherwood and Southport, Queensland, Australia;
  • Hobart, Tasmania, Australia;
  • Malvern East, Victoria, Australia;
  • Tallin and Tartu, Estonia;
  • Baldone, Jekabpils, Liepaja, Ogre and Riga, Latvia;
  • Auckland, Hamilton, Nelson, Tauranga and Wellington, New Zealand;
  • Banska Bystrica, Bratislava and Dubnica Nad Vahom, Slovakia; and,
  • Reading, Berkshire; Chesterfield, Derbyshire; Wellingborough, Northamptonshire: Atherstone, Warwickshire; and
  • Belfast, United Kingdom.

Posts in this series:

strip

Shaken…not Stirred

Purple bondI’m 007…really! That’s my identification number for the Daiichi Sankyo Mirogabalin study. Today, I went for my screening interview.

I got to Emeritus Research at 11am. The place looks like any other office…with 3 assessment rooms at the back, filled with medical equipment. It seems a little disorganised and haphazard; but I’m looking forward to being involved.

I had a meeting with a nurse practitioner and a doctor. They took a very, very long history, asking questions about almost EVERYthing to do with my medical history (including a questionnaire called the MINI, which I must say is just plain stupid!). I was required to give a urine sample (to check if I am pregnant), some blood work and an EKG. The doctor did a relatively quick physical and, of course, checked all my pressure points. All in all, with a few technical issues, it took about 2 hours.

The first part of the study is 13 weeks long. I have to come off the Lyrica that I am already on. Then I will be (randomly) assigned to one of 4 groups: Placebo, 300mg Lyrica, 15mg Mirogabalin or 30mg Miroglabin. There will be regular check-ups for the entire time.

After the 13 week trial, there may be an opportunity to enter the 52 week Miroglabin trial.

So, now, I’m waiting two weeks to see if I’m part of the study.

NOTE: Emeritus Research is still recruiting for the study, if anybody is interested. Click for  the Consent Form and information. Contact Daiichi using this email address – SM_DS5565_FM_Info@incresearch.com.

As well as the 1000 person study in the US and Canada, Daiichi is also recruiting in:

  • Campse and Coffs Harbour, NSW, Australia;
  • Maroochydore, Sherwood and Southport, Queensland, Australia;
  • Hobart, Tasmania, Australia;
  • Malvern East, Victoria, Australia;
  • Tallin and Tartu, Estonia;
  • Baldone, Jekabpils, Liepaja, Ogre and Riga, Latvia;
  • Auckland, Hamilton, Nelson, Tauranga and Wellington, New Zealand;
  • Banska Bystrica, Bratislava and Dubnica Nad Vahom, Slovakia; and,
  • Reading, Berkshire; Chesterfield, Derbyshire; Wellingborough, Northamptonshire: Atherstone, Warwickshire; and
  • Belfast, United Kingdom.

strip

It’s a Knock Out?

Daiichi Sankyo, a Japanese drug company, is confident it’s struck gold with its’ new drug, Mirogabalin. Daiichi Sankyo believes it will be more potent, have fewer side-effects and be longer-acting than Lyrica. That’s could be a one-two punch combination for many of usmouse who either didn’t derive benefit from the Lyrica or not enough benefit to stay on it.

A major fibromyalgia drug trial is underway in the U.S and Canada. (Want to be part of it? Contact Daiichi using this email – SM_DS5565_FM_Info@incresearch.com. Ninety-four study locations are present in the U.S. and Canada.).

Daiichi Sankyo believes mirogabalin is a significant upgrade on Lyrica. A 2014 study suggested that mirogabalin’s may be 17 times more potent than Lyrica. Both drugs bind to calcium channels that have been implicated in the production of neuropathic pain. Mirogabalin is believed to bind to a calcium channel subunit that has strictly analgesic properties. Lyrica, on the other hand, also binds to another subunit that has central nervous system effects – this is what may be responsible for its side effects.

A 1,000 person U.S./Canadian trial is assessing mirogabalin’s effectiveness in fibromyalgia. The trial makeup – putting the two drugs head to head – indicates Daiichi wants to topple the frontrunner and install mirogabalin as the preferred drug for FM.

Read more: The Next Lyrica? Thousand Person Fibromyalgia Drug Trial is Underway

strip